| Jiying Technology Co., Ltd. participates in the China-U.S. Health Industry Forum |
Related Information Links: 中美大健康产业论坛在香港成功举办-香港新闻社 中美大健康產業論壇在香港成功舉辦-香港盛事公众号 中美大健康產業論壇在香港成功舉辦 - 中華時報China Times 中美大健康产业论坛在香港成功举办-网易新闻
On January 16, 2025, the China-U.S. Health Industry Investment and Mergers & Acquisitions Alliance and the Asia Family Office Foundation jointly held the “Promoting the Integrated Development of AI and Biotechnology, and Building a Bridgehead for Chinese Enterprises to Go Global —— Closed-door 50-person Forum of the China-U.S. Health Industry Investment and Mergers & Acquisitions Alliance” at the Connaught Centre in Central, Hong Kong. The forum focused on the cooperation opportunities in biotechnology, artificial intelligence, and the health industry, with particular emphasis on Hong Kong’s significant role as a global center for biotech innovation. It specifically discussed how scientific and technological advancements can accelerate the research and industrialization of biopharmaceuticals, leveraging Hong Kong’s financial and technological strengths to support the global development of enterprises.
Mr. He Song, CEO of Jiying Technology, attended the forum as the company representative. Since its establishment in Hong Kong in 2019, Jiying Technology has been committed to innovative research and development in the fields of artificial intelligence and biotechnology. With a core focus on integrating AI and genomics, the company is dedicated to developing world-leading medical technology products, such as Genoimage, the world’s first imaging genomics-based auxiliary diagnostic product for gastrointestinal cancer screening. These technologies not only improve diagnostic and therapeutic efficiency but also reduce medical costs, aligning perfectly with the forum’s theme of “Promoting the Integrated Development of AI and Biotechnology.”
The forum provided Jiying Technology with an international platform to showcase its innovative technologies and concepts. Mr. He Song shared the company’s latest progress in the integration of AI and genomics with other industry leaders and gained a deeper understanding of the China-U.S. Health Industry Investment and Mergers & Acquisitions Alliance. He also expressed his anticipation for future similar forums and high-level exchanges organized by the alliance and looked forward to potential cooperation with other global biotech companies.
|
首页